Investors with significant funds have taken a bullish position in Pfizer PFE, a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in PFE usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 12 options transactions for Pfizer. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 75% being bullish and 25% bearish. Of all the options we discovered, 11 are puts, valued at $678,378, and there was a single call, worth $28,500.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $35.0 for Pfizer during the past quarter.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $22.5 to $35.0 in the last 30 days.
Pfizer Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | PUT | TRADE | BEARISH | 03/15/24 | $27.50 | $217.8K | 25.1K | 2.1K |
| PFE | PUT | SWEEP | BULLISH | 01/16/26 | $22.50 | $69.4K | 4.9K | 2.1K |
| PFE | PUT | TRADE | BULLISH | 01/17/25 | $22.50 | $67.6K | 29.8K | 239 |
| PFE | PUT | SWEEP | BULLISH | 12/19/25 | $25.00 | $53.9K | 9.5K | 348 |
| PFE | PUT | SWEEP | BEARISH | 09/20/24 | $29.00 | $51.1K | 820 | 151 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Current Position of Pfizer
- Trading volume stands at 18,437,823, with PFE's price down by -1.13%, positioned at $26.62.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 85 days.
What Analysts Are Saying About Pfizer
2 market experts have recently issued ratings for this stock, with a consensus target price of $45.0.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45.
- Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
